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Five sub types of muscarinic receptors have been 
identified by pharmacological and molecular biolog-
ical methods. The muscarinic receptor subtype medi-
ating acid secretion at the level of the parietal cell 
was unknown. Therefore, this study was performed 
to characterize muscarinic receptors on rat gastric 
parietal cells using the 3 subtype-selective antago-
nists hexahydrosiladifenidol and silahexocyclium, 
which have high affinity for glandular M3 subtypes, 
and AF-DX 116, which has high affinity to cardiac M2 
receptors. The affinity of these antagonists was deter-
mined by radio ligand binding experiments. In addi-
tion, their inhibitory potency on carbachol-stimu-
lated inositol phosphate production was investigated. 
Inhibition of carbachol-stimulated aminopyrine up-
take was used as an indirect measure of proton 
production. Hoth M3 antagonists, hexahydrosi-
ladifenidol and silahexocyclium, had nanomolar af-
finities for parietal cell muscarinic receptors and 
potently antagonized inositol phosphate production 
with nanomolar Ki values. Silahexocyclium simi-
larly antagonized aminopyrine accumulation while 
hexahydrosiladifenidol behaved as a noncompetitive 
antagonist. AF-DX 116 was a low-affinity ligand and a 
weak competitive antagonist at parietal-cell mus ca-
rinic receptors. It was concIuded that muscarinic M3 
receptors mediate acid secretion probably by activa-
tion of the phosphoinositide second messenger sys-
tem in rat gastric parietal cells. 
Muscarinic cholinergic receptors have originaIly been subclassified by their different affinities 
for the nonclassical muscarinic antagonist piren-
zepine (1,2), which has high affinity for neuronal Ml 
and low affinity for non-Ml receptors. Based on 
molecular cloning of muscarinic receptors, there is 
now evidence for 5 different subclasses (3-5). Antago-
nists such as AF-DX 116 (6) were more potent in 
antagonizing muscarinic actions in cardiac M2 than in 
smooth muscle M3 (previously termed M2ß) receptors. 
Compounds such as hexahydrosiladifenidol (HHSiD) 
and silahexocyclium (SiHC] possess 10-30-fold higher 
affinity for smooth muscle and glandular M3 than 
cardiac M2-receptor subtypes (7,8). 
We have previously analyzed the radioligand bind-
ing properties of muscarinic M2 receptors in homoge-
nates of porcine gastric mucosa (9). These data showed 
that HHSiD had high affinity (Kd = 3 nM) to the 
majority of mucosal receptors while AF-DX 116 had 
low affinity (Kd = 3000 nM) compatible with the M3 
subtype. However, approximately 250/0 of the binding 
sites in mucosa had low affinity for HHSiD, suggesting 
the presence of a second subtype of muscarinic recep-
tors. Muscarinic non-Ml receptors in enriched gastric 
parietal ceIls (10) activate the phosphoinositol system, 
which probably provides the second messengers acti-
vating acid secretion (10-13). This model system al-
lows a characterization of the muscarinic receptor 
sub type iqvolved in acid secretion by both functional 
and radioligand binding studies (14,15). The aim of the 
present study was to characterize the muscarinic 
receptor subtype involved in the breakdown of phos-
phatidylinositols and proton production in isolated rat 
gastric parietal ceIls. To this end the inhibitory poten-
cies of prototypic muscarinic M2 and M3 receptor-
Abbreviations used in this paper: dB-cAMP, dibutyryl cyclic 
adenosine monophosphate; HHSiD, hexahydrosiladifenidol; NMS, 
('H)-N-methylscopolamine; SiHe, silahexocycIium. 
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subtype-selective antagonists were determined in 
functionaI and radioligand binding studies. 
Methods and Materials 
Rat gastric mucosal cells were iso la ted anc! enriched 
to a parietal cell content of 720/0 ± 5% cell number as 
described (10). Buffer of the following composition was used 
in all experiments: NaCI, 70 mM; KCl, 5 mM; sodium 
phosphate, 1.5 mM; HEPES, 50 mM; sodium bicarbonate, 20 
mM; bovine serum albumin, 0.2%; pH, 7.4. Incubations 
were at 36°C in a Dubnoff shaker (Braun, Melsungen, West 
Germany) under an atmosphere of oxygen and carbon 
dioxide (95%:5%). 
Radioligand Binding Experiments 
Binding experiments were performed at a cell con-
centration of 2 million/mI per sampIe at 36°C using eH)-N-
methylscopolamine (NMS) as radioactive tracer (specific 
activity 71 and 85 Ci/mmol, NEN) as described previously 
(10). Specific bin ding, obtained by subtracting bound radio-
activity in the presence of 1 j,tM atropine, was 73% ± 4% 
(n = 9) of the total bound. Displacement curves were con-
structed by displacing 0.25 nM tritiated NMS with 11-13 
concentrations of unlabeled ligands (Figure 1). Data were 
analyzed with the program "Ligand" (16). Receptor density 
was 8760 ± 610/ cell (n = 5). 
Inositol Phosphate Determination 
Cells were labeled with tritiated myoinositol, and the 
formation of inositol monophosphate was determined as 
described (10) in the presence of LiCI (10 mM) to obtain a 
measure of activation of phospholipase C (17). 
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e4C)Aminopyrine Accumulation 
e4C)Aminopyrine accumulation was determined ac-
cording to the method of Berglindh et al. (14) as described 
previously (10). Aminopyrine accumulation is expressed as 
the ratio of intraglandular radioactivity to that in the super-
natant (10,14). The mean aminopyrine ratio was 6.9 ± 1.3 
(n = 9) for stimulation by 0.1 mM carbachol, 15 ± 4 for 0.1 
mM dibutyryl cyclic adenosine mono phosphate (dB-cAMP), 
and 88 ± 19 for carbachol plus dB-cAMP (n = 5). 
Arunlakshana-Schild Plots 
Arunlakshana-Schild plots were calculated to deter-
mine antagonist affinities (18) by obtaining dose-response 
curves for carbachol (0.1 or 1 j,tM to 10 mM) for aminopyrine 
accumulation and inositol phosphate production in the 
absence and presence of 3 concentrations of antagonists: 
HHSiD, 50-500 nM; SiHC, 40-500 nM; AF-DX, 5-100 j,tM. 
Each experiment was independently performed 3-5 times in 
duplicates for each point, and mean values were used to 
ealculate Ki values. 
Statistical Methods 
Dose-response curves were analyzed with the "Allfit" 
program of DeLean et al. (19), and the statisties implemented 
in the program were used to test for parallelism of the eurves 
(19). Data are indieated as means ±SEM. 
Materials 
The soure es of chemieals and radioehemicals were 
as deseribed (9,10). Silahexoeyelium was synthesized as 
described by Taeke et al. (20). 
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Figure 1. (A) Displacement of NMS by the muscarinic M.ß-receptor-selective antagonists HHSiD and SiRe and by the cardioselective 
antagonist AF-DX 116 in rat gastric parietal cells. Each curve represents mean values from 3-4 independent experiments each performed 
in duplicate. Specific binding was 2153 ± 518 dpm/2 million cells (n = 5). The Unes correspond to one-site fits as determined with the 
curve-fitting program "Ligand" (16). (B) Inhibition of inositol phosphate production stimulated by 0.1 mM carbachol by muscarinic 
antagonists. Basal and stimulated values for inositol phosphate production were 1436 ± 436 and 4740 ± 956 dpm/tube. The curves 
correspond to those determined with the "Allfit" program (19). 
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Results 
The interaction of the muscarinic antagonists 
HHSiD, SiHC, and AF-DX 116 with muscarinic recep-
tors in enriched rat gastric parietal cells was studied 
by radioligand binding experiments. Analysis of the 
displacement curves against (3H)NMS indicated the 
presence of a single dass of bin ding sites with affin-
ities of 6.2 ± 1.6 and 3.2 ± 0.6 nM for HHSiD and 
SiHC, respectively (Figure 1). The M2 antagonist 
AF-DX 116 had a low affinity to the same single site of 
3190 ± 635 nM (Figure 1). 
Carbachol (0.1 mM) caused a 3.3 ± 0.4-fold (n = 6) 
stimulation of inositol phosphate formation. None of 
the antagonists significantly stimulated inositol phos-
phate production at doses of 0.1 nM-l0 JLM (n = 4), 
indicating a lack of partial agonistic activity. The 
stimulation of inositol phosphate production by carba-
chol was completely antagonized by HHSiD, SiHC, 
and AF-DX 116 with IC50 va lues of 58.2 ± 7.7 nM, 
24.7 ± 3.5 nM, and 12.5 ± 2.6 JLM, respectively (Figure 
2). To characterize the type of inhibition and to 
determine antagonist affinities, an analysis according 
to Arunlakshana and Schild (18) was performed. 
Dose-response curves for carbachol were constructed 
in the absence and presence of the antagonists. Con-
centrations of 0.05-0.5 JLM HHSiD and SiHC and 
10-100 JLM AF-DX 116 caused parallel shifts to the 
right of the dose-response curves for carbachol, indic-
ative of competitive inhibition. Schild plots of the data 
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Figure 2. Correlation of receptor binding affinity (Kd) and Ki 
values for inhibition of carbachol-stimulated aminopyrine uptake 
or inositol phosphate production for muscarinie antagonists. 
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Table 1. Antimuscarinic Pateneies of 
Hexahydrosiladifenidol, Silahexocyclium, and 
AF -DX 116 in Isolated Rat Gastric Parietal Cells 
Inositol 
('HJN -methylscopol- phosphate (14CJaminopyrine 
amine bin ding production accumulation 
Kd(nMJ Ki(nMJ Ki(nMJ 
HHSiD 6.2 5.1 (-1.16Jo - b 
SiHC 3.2 1.5 (-1.11J 2.7 (-0.89J 
AF-DX116 3190 3100 (-0.89J 3200 (-0.86J 
oValues in parentheses indicate slopes of Schild plots. bNoncompet-
itive inhibition (see textJ. 
yielded Ki values for HHSiD, SiHC, and AF-DX 116 of 
5.1 nM, 1.5 nM, and 3.1 JLM, respectively (Table 1). 
The accumulation of the weak base aminopyrine in 
the acidic intracellular tubulovesical compartment 
was used to obtain an indirect measure of hydrogen 
ion production by the isolated cells (14,15). The stimu-
lation by 0.1 mM carbachol was inhibited half maxi-
mally by HHSiD at 67 ± 8.5 nM. However, dose-
response curves for carbachol in the presence of 
increasing concentrations of HHSiD showed a shift to 
the right and a flattening of the curves indicative of 
noncompetitive inhibition. Hexahydrosiladifenidol 
also inhibited aminopyrine accumulation stimulated 
by the cell-permeable cAMP analogue dB-cAMP with 
an IC50 of 443 ± 47 nM (n = 4). Because dB-cAMP 
acts intracellularly and thus through a receptor-
independent pathway, HHSiD probably interfered 
with aminopyrine uptake by a receptor-independent 
mechanism. 
Silahexocyclium and AF-DX 116 did not interfere 
with dB-cAMP-stimulated aminopyrine uptake and 
inhibited aminopyrine uptake stimulated by carbachol 
with IC50 values of 24 ± 3 nM and 15.7 ± 3.7 JLM, 
respectively. Increasing concentrations of SiHC and 
AF-DX 116 caused parallel right shifts of dose-
response curves for carbachol suggesting competitive 
inhibition. The Ki of SiHC and AF-DX 116 for inhibi-
tion of aminopyrine uptake determined by Schild 
analysis was 2.7 nM and 3.2 JLM (Table 1). 
Discussion 
The present study attempts a classification of 
the muscarinic receptor sub type that mediates activa-
tion of phospholipase C and acid secretion. In the 
present study we. used 3 receptor-subtype-selective 
antagonists that had previously been shown to distin-
guish cardiac from smooth muscle or glandular musca-
rinic receptors. 
The M3 antagonists, HHSiD and SiHC, had high 
affinity for muscarinic binding sites on isolated rat 
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gastric parietal cells, while the affinity of the M2 
antagonist, AF-DX 116, was low. 
Antagonist potencies were also assessed in terms of 
functional parameters. Inositol phosphate is a metabo-
lite of receptor-activated and phospholipase C-
media ted breakdown of phosphatidyl inositols whieh 
is likely to represent a measure of muscarinie second 
messenger generation (17). Hexahydrosiladifenidol and 
SiHC showed similarly high potencies, while AF-DX 
116 had low potency, in antagonizing carbachol-
stimulated inositol phosphate production (Figure 2). 
All substances behaved as competitive antagonists. 
Hexahydrosiladifenidol and SiHC potently inhib-
ited carbachol-stimulated aminopyrine accumulation, 
whieh was measured to obtain an estimate of acid 
secretion (14,15). In contrast, AF-DX 116 aga in was a 
weak antagonist. To exclude noncompetitive phenom-
ena, we tested effects on receptor-independent, dB-
cAMP-stimulated aminopyrine uptake, whieh should 
not be affected by the antagonists. Although AF-DX 
116 and the quarternary compound, SiHC, did not 
affect dB-cAMP-stimulated aminopyrine uptake, 
HHSiD exerted an inhibitory effect. In addition, 
HHSiD caused a flattening of dose-response curves 
for carbachol. Because HHSiD was a competitive 
antagonist of inositol phosphate production, the non-
competitive action is not related to the receptor inter-
action of the antagonist. The most likely mechanism 
may be a direct interference of the rather hydrophobie 
compound with aminopyrine uptake. 
The Ki values calculated from the data on inositol 
phosphate production and aminopyrine uptake were 
in agreement with Kd values determined by radioli-
gand binding experiments. This suggests that all 3 
effects involved the same type of muscarinie receptor 
(Table 1; Figure 2). The pharmacologieal profile of this 
receptor corresponds to the glandular or M3 subtype 
of muscarinie receptors (1-9). Therefore, the M3 sub-
type is likely to mediate muscarinic stimulation of acid 
secretion via activation of the inositol phosphate sys-
tem at the parietal celllevel. 
Baudiere et al. (13) recently determined the potency 
of HHSiD in isolated rabbit gastrie cells with regard to 
both receptor-binding affinity and inhibition of ami-
nopyrine uptake. The affinity of HHSiD was <200 nM 
Kd in bin ding studies, and the Ki for inhibition of 
aminopyrine accumulation was 79 nM. The investiga-
tors did not indicate that noncompetitive phenomena 
were observed. The discrepancy compared with our 
study may relate to species-specific differences. 
The primary structures of 5 different types of musca-
rinie receptors have been derived from the cloned 
nucleotide sequences, and their characteristies have 
been investigated after transfection into various cell 
types (3-5). The bin ding data obtained with AF-DX 
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116, HHSiD, and SiHC for the M3 receptor, which 
strongly activates phosphoinositide breakdown but 
does not inhibit adenylate cyclase (5), were similar to 
those observed in the present study. Thus, the subtype 
designated either m3 or mACh-III (3,4) or HM4 (5) 
most likely corresponds to the M3 receptor present in 
rat parietal cells. Because this subtype is also present 
on submandibular and pancreatic cells, it may repre-
sent an important gastrointestinal and glandular mus-
carinie receptor. Isolated rat gastrie parietal cells 
should provide a well-defined system for the molecu-
lar, biochemieal, and functional characterization of 
this partieular muscarinic receptor subtype. 
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